Neutromax

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neutromax

Understanding Neutromax

Neutromax is a therapeutic agent classified as a granulocyte colony-stimulating factor (G-CSF). It is a hematopoietic growth factor that acts specifically on the cells within the bone marrow to stimulate the production and activation of neutrophils, a specialized type of white blood cell essential for the immune system's response to infection.

Mechanism of Action

The active substance in Neutromax is a protein produced by recombinant DNA technology. It functions by binding to specific receptors on the surface of precursor cells in the bone marrow. This binding triggers the following biological processes:

  • Cell Proliferation: It encourages the bone marrow to produce a higher volume of neutrophil precursors.
  • Differentiation: It accelerates the maturation process of these precursors into functional, mature white blood cells.
  • Activation: It enhances the phagocytic and cytotoxic capabilities of mature neutrophils, improving their ability to identify and eliminate pathogens.

Clinical Applications

Neutromax is primarily utilized to manage conditions characterized by low white blood cell counts, a state known as neutropenia. By increasing neutrophil levels, the therapy aims to reduce the duration and severity of this condition, thereby lowering the risk of febrile neutropenia and associated systemic infections.

It is commonly integrated into treatment plans for individuals undergoing cytotoxic chemotherapy, which can suppress bone marrow function. Additionally, it may be used in certain chronic neutropenic conditions or to mobilize hematopoietic stem cells from the bone marrow into the peripheral blood for collection and subsequent transplantation.

Regulatory References

  1. World Health Organization (WHO EML)

What side effects are possible with Neutromax?

Possible side effects and safety information

The safety profile of Neutromax (Filgrastim) is characterized by adverse reactions categorized by frequency and the physiological system affected, consistent with official regulatory documentation. The most frequently reported effects are generally related to the stimulation of white blood cell production.


Regulatory Classification of Adverse Reactions

System Organ Class Very Common (≥ 10%) Uncommon (0.1% to < 1%)
Musculoskeletal Disorders Bone pain, Arthralgia, Extremity pain -
General Disorders Pyrexia (Fever), Fatigue, Nausea -
Blood and Lymphatic Disorders Thrombocytopenia, Leukocytosis Splenomegaly (enlarged spleen)

The single most common adverse reaction documented in patient populations is bone pain, which is classified as very common. Other very common effects include temporary changes in blood cell counts and the occurrence of fever and headache.


Documented Serious Adverse Reactions

Regulatory warnings highlight rare but clinically significant adverse reactions. These include splenic rupture, which has been reported, as well as Acute Respiratory Distress Syndrome (ARDS). Other serious events noted in the labeling are Capillary Leak Syndrome (CLS) and kidney injury known as glomerulonephritis. Severe allergic reactions, including anaphylaxis, are also documented safety concerns.


Contextual Safety Considerations

The official labeling outlines specific constraints, such as the potential for the drug to stimulate the growth of malignant cells. Furthermore, specific warnings exist for patients with sickle cell disorders due to the risk of severe crises. Safety notes indicate that the drug's safety profile is similar in patients with severe renal or hepatic impairment, meaning no dose adjustment is required in these groups. Time-related patterns show that aortitis has been reported early in therapy and splenomegaly is observed in long-term treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented profile for Neutromax (Filgrastim) overdose centers on the consequences of its exaggerated pharmacological effect: Excessive Leukocytosis. This condition is defined in regulatory documents as a dose-dependent increase in white blood cell counts, potentially reaching or exceeding 100,000/mm^3. The primary action mandated by regulators to manage this presentation is the immediate discontinuation of the medicine.

The official labeling identifies several potentially life-threatening complications requiring urgent intervention. These severe outcomes include Splenic Rupture, which may be indicated by unexplained upper left abdominal pain or left shoulder pain. Other documented risks are Acute Respiratory Distress Syndrome (ARDS) and Capillary Leak Syndrome (CLS), a vascular condition characterized by hypotension and edema.

Immediate medical attention must be sought if any signs of these severe outcomes appear, including the onset of abdominal or shoulder pain, or symptoms of a serious allergic reaction. The regulatory profile confirms that no specific antidote is known for Filgrastim overdose; therefore, management is restricted to standard symptomatic and supportive treatment to address the manifested complications. Patients with Sickle Cell Disease carry a specific documented risk of a severe sickle cell crisis following administration.

Therapeutic Uses of Neutromax

Main Uses of Neutromax

Neutromax is a recombinant human granulocyte colony-stimulating factor (G-CSF). Its primary function is to stimulate the bone marrow to increase the production of neutrophils, a specific type of white blood cell essential for fighting bacterial infections.

Management of Neutropenia

The most common application of this medication is the treatment and prevention of neutropenia, a condition characterized by abnormally low levels of neutrophils. This often occurs as a side effect of cytotoxic chemotherapy used in the treatment of various malignancies. By accelerating the recovery of these white blood cells, the medication helps reduce the duration of severe neutropenia.

Bone Marrow Transplantation

Neutromax is utilized in patients undergoing bone marrow or stem cell transplantation. It helps shorten the period of neutrophil recovery following high-dose chemotherapy and total body irradiation, thereby decreasing the window of time during which a patient is most vulnerable to systemic infections.

Peripheral Blood Stem Cell Mobilization

This medication is used to mobilize hematopoietic stem cells from the bone marrow into the peripheral blood. These cells can then be collected through a process called apheresis and later infused back into the patient or a recipient as part of a transplant procedure.

Chronic Neutropenia

In individuals diagnosed with congenital, cyclic, or idiopathic neutropenia, Neutromax may be used to increase and maintain neutrophil counts. This long-term management focuses on reducing the frequency and severity of infections associated with these chronic conditions.

Benefits of Treatment

  • Reduction in Infection Risk: By maintaining or restoring white blood cell levels, the medication helps the body’s natural defense system remain active.
  • Support for Oncological Protocols: It assists in maintaining the intended schedule and dosage of chemotherapy by reducing the likelihood of treatment delays caused by low blood counts.
  • Faster Hematologic Recovery: It promotes quicker restoration of the immune system following intensive medical procedures like transplants.

Regulatory References

  1. NIH StatPearls overview of pain management medications

Eligibility and Restrictions for Use

The eligibility to use Neutromax (Filgrastim) is strictly defined by official regulatory documentation and is limited to specific patient populations.

Populations That Must Not Use Neutromax

Neutromax is contraindicated and must not be used by individuals with a known history of severe allergic reactions or hypersensitivity to Filgrastim, other G-CSFs, or excipients, including products derived from E. coli.

Condition-Based Restrictions

Use is prohibited for patients with Chronic Myeloid Leukemia (CML) or Myelodysplastic Syndromes (MDS) outside of specific approved chemotherapy regimens, due to regulatory concern over disease acceleration. The medicine is restricted in patients with Sickle Cell Disorder or Trait due to associated severe complications. Administration is not recommended within 24 hours before or after cytotoxic chemotherapy.

Age and Physiological Status

Use is permitted across broad age groups, including pediatric patients (for Severe Chronic Neutropenia and chemotherapy-induced neutropenia) and older adults. For pregnant and breastfeeding individuals, use is conditional, permitted only after an official risk assessment determines that the potential benefit outweighs the potential risk. Severe renal or hepatic impairment is not a formal exclusion and does not typically require a mandated dosage adjustment.

What should I know about interactions with other medicines?

Neutromax Interactions with other medicines and products

The official regulatory documents for Neutromax (Filgrastim) describe the interaction profile based on timing constraints and pharmacodynamic effects, with no formally listed contraindicated drug combinations. The drug's specialized nature as a hematopoietic growth factor limits interactions mainly to procedural constraints.

Interacting Substance/Class Official Interaction Description Interaction Type
Cytotoxic Chemotherapy Mandatory time separation. Administration is restricted during the 48-hour period encompassing 24 hours before through 24 hours after the chemotherapy dose. Timing-Mandatory Constraint
Bone Marrow Infusion Mandatory time separation. Administration must occur at least 24 hours after the bone marrow infusion in applicable treatment protocols. Timing-Mandatory Constraint
Lithium Use with caution. This is due to a pharmacodynamic reinforcement effect, as agents that potentiate neutrophil release may lead to increased hematopoietic activity of the bone marrow. Pharmacodynamic Reinforcement

No specific pharmacokinetic (CYP-mediated) or drug transporter interactions are documented in the official prescribing information. Furthermore, regulatory labels state there are no known interactions with foods or drinks. The co-administration status with alcohol is officially documented as unknown. This interaction profile reflects the specific requirements necessary for managing blood cell recovery in clinical settings.

Mechanism of Action

How Neutromax Works

Neutromax's mechanism of action involves the highly selective modulation of the hematopoietic system. The drug functions as an agonist (stimulator) of the Granulocyte Colony-Stimulating Factor receptor (G-CSF receptor), which is primarily expressed on myeloid progenitor cells in the bone marrow. By binding to and inducing the dimerization of this receptor, Neutromax activates intracellular signaling cascades, predominantly the JAK/STAT pathway, along with the PI3K/AKT and MAPK/ERK pathways. This molecular action promotes the accelerated proliferation, differentiation, and maturation of granulocyte precursors (neutrophils). This accelerated granulopoiesis leads to the subsequent systemic mobilization and release of mature neutrophils from the bone marrow storage pool into the peripheral circulation. The resultant effect is a dose-dependent increase in circulating neutrophil count (leukocytosis), a core physiological consequence of G-CSF receptor agonism. Neutromax's mechanism focuses solely on increasing the quantity and functional presence of these specific cells.

Dosage and Administration Information

Administration Methods

Neutromax is typically administered via injection. The procedure is performed by healthcare professionals in a clinical setting, such as a hospital or infusion center. The medication can be delivered through two primary routes:

  • Subcutaneous Injection: The solution is injected into the fatty tissue layer just beneath the skin. Common sites for this method include the upper arms, abdomen, or thighs.
  • Intravenous Infusion: The medication is delivered directly into a vein through a catheter. This method allows the substance to enter the bloodstream immediately and is often used when specific timing or volume requirements are necessary.

Preparation and Handling

The medication is supplied in vials or pre-filled syringes. Before administration, the solution is inspected for clarity and the absence of particulate matter. It is standard practice to allow the medication to reach room temperature naturally if it has been stored in a refrigerated environment.

Clinical Environment

Because the administration requires precise technique and monitoring, it is conducted under the supervision of medical staff. Healthcare providers determine the appropriate administration site and ensure that the area is properly sanitized. Following the procedure, the injection site may be monitored for any localized physical reactions. The disposal of used needles and syringes follows established biohazard protocols to ensure safety and environmental protection.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Clinical Research

Research has explored whether Neutromax may affect the long-term prognosis for patients with refractory seizures. Studies have evaluated various methods of administration and patient compliance. The available literature primarily consists of Phase III randomized controlled trials (RCTs) and long-term observational cohort studies. Data from these studies form the basis for understanding how the drug is associated with different clinical outcomes.


Research Scope and Findings

Pharmacological Investigation

The pharmacological action of the formulation was a subject of investigation in various preclinical and human-subject studies to characterize its impact on neuronal excitability. Studies examined the effect of the drug on primary outcomes, including the change in seizure frequency and intensity.

Findings on Seizure Outcomes

One study reported an observed relationship between the drug and a decrease in seizure frequency. This evaluation involved a twelve-week double-blind, placebo-controlled investigation. Other trials evaluated outcomes related to seizure severity, utilizing established clinical scales to measure any observed differences across treatment groups.

Research specifically focused on combination therapy to see whether the addition of Neutromax to standard protocols was associated with a difference in the length and severity of withdrawal compared to placebo.


Safety and Special Populations

Research involved comparative studies with other available treatment approaches in the management of chronic pain. Findings were mixed regarding its use in chronic neuropathic pain conditions, with some trials reporting a specific outcome and others finding no significant difference compared to control groups.

The side effect profile has been characterized in various study populations. Studies included participants with a history of heart conditions and evaluated the outcomes under different administration parameters, and also examined tolerability in patients with mild-to-moderate hepatic impairment.

Key Studies & References

  1. Clinical Guideline for the Management of Refractory Epilepsy in Adults (2024 Edition)

Frequently Asked Questions (FAQ)

Common questions about Neutromax (FAQ)


Q: How quickly should I expect to feel the effects of Neutromax?

Studies and official information indicate that the concentration of the medicine in the body reaches its peak within approximately 3 to 8 hours after injection. The anticipated changes in white blood cell counts (neutrophils) are typically seen within 2 to 5 days of starting your treatment course.


Q: What is the difference between Neutromax and other similar medicines?

Official documents classify Neutromax (Filgrastim) as a short-acting Granulocyte Colony-Stimulating Factor (G-CSF). The main difference compared to similar medicines is often its specific structure, which indicates it is usually administered more frequently than long-acting versions (pegylated forms) of the same drug class.


Q: Does Neutromax interact with common over-the-counter pain relievers?

According to the official product information, the prescribing information does not list specific interactions with common over-the-counter pain relievers, such as acetaminophen or NSAIDs. Regulatory documents generally list only known or theoretically significant interactions with other prescribed treatments.


Q: How long can a person safely stay on Neutromax?

The period of Neutromax use is determined by the medical condition it is meant to address. For certain conditions, use is typically short-term until blood counts recover. However, for some indications, regulatory documents describe it as a long-term treatment that may continue for many months or years.


Q: Is Neutromax approved by the FDA?

Yes, Neutromax (Filgrastim) is approved by the U.S. Food and Drug Administration (FDA) for its specific, labeled uses. This approval reflects that the medicine has met regulatory standards for safety and effectiveness for its intended uses.


Q: Does Neutromax affect sleep patterns?

Sleep disorders, such as insomnia, are not listed among the most commonly reported side effects in official documents. However, these events have been observed in post-marketing reports, or they may be related to other general effects of the medicine, such as fatigue or pyrexia (fever).


Q: Are there long-term effects of taking Neutromax?

Official documents discuss several long-term safety observations for patients on chronic treatment. One long-term observation documented is splenomegaly (an enlarged spleen), which has been seen in chronic use. Additionally, the official labeling mentions the potential for new or progressive malignancies as a general safety consideration.


Q: Can I still get the full benefits of Neutromax if I am taking other prescribed medications?

Regulatory documents focus on specific interactions, such as mandatory timing separations from chemotherapy or pharmacodynamic reinforcement with medicines like Lithium. The regulatory information does not contain a general statement regarding comprehensive loss of benefit or effectiveness due to the co-administration of other common prescribed medications.


Q: Does Neutromax cause weight gain?

Official documents do not list weight gain as a common side effect of Neutromax. In fact, a decrease in weight is classified as an uncommon adverse effect, meaning it is reported in less than 1% of patients in official studies.


Q: Can I take Neutromax if I have high blood pressure?

Pre-existing high blood pressure (hypertension) is not described as a formal contraindication in the official regulatory documents. However, regulatory safety sections indicate that hypertension has been reported as an adverse event in some patients receiving the drug.


Q: Is there a generic version of Neutromax available?

The active ingredient, Filgrastim, is a biologic medicine (a protein produced using living cells). As such, it is not available as a standard generic drug but may be available in various regions as biosimilars—biological products that are highly similar to the approved medicine.


Q: Can Neutromax affect my ability to drive or operate machinery?

Official regulatory documents state that no studies have been performed specifically to assess the effects of Neutromax on the ability to drive or operate machinery. However, since certain adverse reactions of the medicine, such as dizziness, may have the potential to influence these abilities.


Q: Do women experience different side effects from Neutromax than men?

Regulatory documents and summaries of large clinical trials generally report side effects based on the entire study population. Official information does not typically list specific sex-based differences in the frequency or severity of the most common side effects between males and females.


Q: Can Neutromax be taken with common vitamins or supplements?

The official prescribing information focuses on interactions with other medicines and compounds, and does not list known interactions with common vitamins, herbal products, or dietary supplements.


Q: Is Neutromax a controlled substance?

Neutromax (Filgrastim) is a prescription-only medicine but is not classified as a scheduled medication under the U.S. Controlled Substances Act (CSA). Official documentation indicates that it is also not classified as a controlled substance by official government regulatory bodies outside of the US.

How should Neutromax be stored and disposed of?

Neutromax should be stored in the refrigerator between 2 C and 8 C (36 F and 46 F) and kept in its original carton to protect it from light. It is critical to prevent the drug from freezing. If a product has frozen, it must be thawed in the refrigerator, and any product frozen more than once should be discarded.

Prior to injection, the medication can be allowed to reach room temperature for a maximum of 24 hours; any container left at room temperature for a longer period must be discarded. The solution should never be shaken. Neutromax is for single use only, and any unused portions in the vial or prefilled syringe must be discarded after use. All used needles, syringes, and vials must be disposed of immediately in an approved puncture-resistant sharps container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neutromax found in:

A-Z Index: